
Findings from Boehringer Ingelheim’s recent rollout of AI in Pharmacovigilance (PV)
What was the opportunity? Claudia Lehman, Boehringer Ingelheim (CL): We had already seen considerable

What was the opportunity? Claudia Lehman, Boehringer Ingelheim (CL): We had already seen considerable